RATIONALE: Asthma is characterized by disordered airway physiology as a consequence of increased airway smooth muscle contractility. The underlying cause of this hypercontractility is poorly understood. OBJECTIVES: We sought to investigate whether the burden of oxidative stress in airway smooth muscle in asthma is heightened and mediated by an intrinsic abnormality promoting hypercontractility. METHODS: We examined the oxidative stress burden of airway smooth muscle in bronchial biopsies and primary cells from subjects with asthma and healthy controls. We determined the expression of targets implicated in the control of oxidative stress in airway smooth muscle and their role in contractility. MEASUREMENTS AND MAIN RESULTS: We found that the oxidative stress burden in the airway smooth muscle in individuals with asthma is heightened and related to the degree of airflow obstruction and airway hyperresponsiveness. This was independent of the asthmatic environment as in vitro primary airway smooth muscle from individuals with asthma compared with healthy controls demonstrated increased oxidative stress-induced DNA damage together with an increased production of reactive oxygen species. Genome-wide microarray of primary airway smooth muscle identified increased messenger RNA expression in asthma of NADPH oxidase (NOX) subtype 4. This NOX4 overexpression in asthma was supported by quantitative polymerase chain reaction, confirmed at the protein level. Airway smooth muscle from individuals with asthma exhibited increased agonist-induced contraction. This was abrogated by NOX4 small interfering RNA knockdown and the pharmacological inhibitors diphenyleneiodonium and apocynin. CONCLUSIONS: Our findings support a critical role for NOX4 overexpression in asthma in the promotion of oxidative stress and consequent airway smooth muscle hypercontractility. This implicates NOX4 as a potential novel target for asthma therapy.
RATIONALE: Asthma is characterized by disordered airway physiology as a consequence of increased airway smooth muscle contractility. The underlying cause of this hypercontractility is poorly understood. OBJECTIVES: We sought to investigate whether the burden of oxidative stress in airway smooth muscle in asthma is heightened and mediated by an intrinsic abnormality promoting hypercontractility. METHODS: We examined the oxidative stress burden of airway smooth muscle in bronchial biopsies and primary cells from subjects with asthma and healthy controls. We determined the expression of targets implicated in the control of oxidative stress in airway smooth muscle and their role in contractility. MEASUREMENTS AND MAIN RESULTS: We found that the oxidative stress burden in the airway smooth muscle in individuals with asthma is heightened and related to the degree of airflow obstruction and airway hyperresponsiveness. This was independent of the asthmatic environment as in vitro primary airway smooth muscle from individuals with asthma compared with healthy controls demonstrated increased oxidative stress-induced DNA damage together with an increased production of reactive oxygen species. Genome-wide microarray of primary airway smooth muscle identified increased messenger RNA expression in asthma of NADPH oxidase (NOX) subtype 4. This NOX4 overexpression in asthma was supported by quantitative polymerase chain reaction, confirmed at the protein level. Airway smooth muscle from individuals with asthma exhibited increased agonist-induced contraction. This was abrogated by NOX4 small interfering RNA knockdown and the pharmacological inhibitors diphenyleneiodonium and apocynin. CONCLUSIONS: Our findings support a critical role for NOX4 overexpression in asthma in the promotion of oxidative stress and consequent airway smooth muscle hypercontractility. This implicates NOX4 as a potential novel target for asthma therapy.
Authors: Christopher E Brightling; Fiona A Symon; Surinder S Birring; Peter Bradding; Ian D Pavord; Andrew J Wardlaw Journal: J Allergy Clin Immunol Date: 2002-12 Impact factor: 10.793
Authors: Christopher E Brightling; Peter Bradding; Fiona A Symon; Stephen T Holgate; Andrew J Wardlaw; Ian D Pavord Journal: N Engl J Med Date: 2002-05-30 Impact factor: 91.245
Authors: P Panina-Bordignon; A Papi; M Mariani; P Di Lucia; G Casoni; C Bellettato; C Buonsanti; D Miotto; C Mapp; A Villa; G Arrigoni; L M Fabbri; F Sinigaglia Journal: J Clin Invest Date: 2001-06 Impact factor: 14.808
Authors: Patrick Berger; Pierre-Olivier Girodet; Hugues Begueret; Olga Ousova; Diahn-Warng Perng; Roger Marthan; Andrew F Walls; J Manuel Tunon de Lara Journal: FASEB J Date: 2003-09-18 Impact factor: 5.191
Authors: D Kaur; F Hollins; R Saunders; L Woodman; A Sutcliffe; G Cruse; P Bradding; C Brightling Journal: Clin Exp Allergy Date: 2009-12-16 Impact factor: 5.018
Authors: Jean Bousquet; Eva Mantzouranis; Alvaro A Cruz; Nadia Aït-Khaled; Carlos E Baena-Cagnani; Eugene R Bleecker; Chris E Brightling; Peter Burney; Andrew Bush; William W Busse; Thomas B Casale; Moira Chan-Yeung; Rongchang Chen; Badrul Chowdhury; Kian Fan Chung; Ronald Dahl; Jeffrey M Drazen; Leonardo M Fabbri; Stephen T Holgate; Francine Kauffmann; Tari Haahtela; Nikolaï Khaltaev; James P Kiley; Mohammad R Masjedi; Yousser Mohammad; Paul O'Byrne; Martyn R Partridge; Klaus F Rabe; Alkis Togias; Christiaan van Weel; Sally Wenzel; Nanshan Zhong; Torsten Zuberbier Journal: J Allergy Clin Immunol Date: 2010-11 Impact factor: 10.793
Authors: G Teixeira; C Szyndralewiez; S Molango; S Carnesecchi; F Heitz; P Wiesel; J M Wood Journal: Br J Pharmacol Date: 2016-07-14 Impact factor: 8.739